MedPath

Remote Temperature Data for Early Detection of Febrile Neutropenia

Completed
Conditions
Hematologic Malignancy
Interventions
Device: BioSticker
Registration Number
NCT05180838
Lead Sponsor
University of Colorado, Denver
Brief Summary

BioSticker data is remotely tracked and displayed in a report termed the BioReport for retrospective data analysis. Typically, the biosensor collects data on an interval of \~1 minute and this data is collated and reported remotely back to the BioReport every 6 hours. More importantly, for future applications of the BioSticker for early detection of FN, there are ongoing efforts to implement real time reporting and alarms using remote monitoring services that could alert the patient that they need to seek medical care. There are no known deleterious effects from the BioSticker and it is now being widely used and tested in diverse applications including detection and contact tracing of COVID and others.

Detailed Description

The BioIntelliSense BioSticker potentially offers a solution to these challenges through early and reliable detection of elevated temperature and perhaps other relevant physiologic changes. The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring (see https://biointellisense.com as well as attached documents on BioSticker instructions for a full description and use instructions). The BioSticker detects the following:

* Respiratory rate, heart rate at rest and skin temperature

* Body position, activity levels, sleep status

* High-resolution gait analysis and fall detection

* Symptomatic events

BioSticker data is remotely tracked and displayed in a report termed the BioReport for retrospective data analysis. Typically, the biosensor collects data on an interval of \~1 minute and this data is collated and reported remotely back to the BioReport every 6 hours. More importantly, for future applications of the BioSticker for early detection of FN, there are ongoing efforts to implement real time reporting and alarms using remote monitoring services that could alert the patient that they need to seek medical care. There are no known deleterious effects from the BioSticker and it is now being widely used and tested in diverse applications including detection and contact tracing of COVID and others.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Ages 18-80 years (inclusive)
  • Provision to sign and date the consent form.
  • Diagnosed with a hematologic malignancy and undergoing cytotoxic chemotherapy, stem cell transplants or CAR T-cell treatments at the Blood Disorders and Cell Therapies Center at UCHealth (BDCTC)
  • Will have longitudinal care provided by the BDCTC for >1 additional month
  • Receive chemotherapy or other therapies known to cause reductions in WBC <1000 on a routine basis
  • Scheduled to be discharged home and self-monitor for FN and other complications
  • Patient is willing to tell TSA or any security representative that you are wearing a "medical device"
  • Patient has agreed to not submerge the device underwater including while swimming or bathing
  • Patient is willing to complete a self-check temperature log comply and be available for the duration of the study
  • Patient has access to a thermometer
Read More
Exclusion Criteria
  • Patient that wears a defibrillator, pacemaker, or other implantable device
  • Patient has broken skin including wounds, sores, or abrasions in the area that the BioSticker would be applied
  • Patient has had a severe reaction to silicone adhesives
  • Patient has any clinically significant medical or psychiatric disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
BioStickerBioStickerThis cohort will place BioStickers at least 3 days prior to completion of standard of care therapy and discharge home post therapy.
Primary Outcome Measures
NameTimeMethod
Reliability of BioSticker compared to self-check28 days

Patients will self-temperature check every 6 hours or at least two times per day, and will log these temperatures in a paper record with date, time and temperature noted.

Secondary Outcome Measures
NameTimeMethod
BioSticker Impact on Delays in Chemotherapy28 days

Delays in chemotherapy during the 28 days will be extracted from the medical record

BioSticker Impact on Length of Hospitalization28 days

Hospitalization during the 28 days will be extracted from the medical record

BioSticker Impact on Patient reported temperature28 days

Patients will report a single oral temperature of ≥38.3°C (101°F) or a temperature of ≥38.0°C (100.4°F) sustained over a one-hour period to our clinic nurses or 24/7 on-call advanced practitioner and will be directed to the Emergency Department or clinic for initiation of antibiotics and FN work-up and management as per usual practice.

BioSticker Impact on ICU transfers28 days

ICU transfers during the 28 days will be extracted from the medical record

Trial Locations

Locations (2)

Colorado Research Center

🇺🇸

Aurora, Colorado, United States

UCHealth-Metro Denver

🇺🇸

Denver, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath